{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:07:04Z","timestamp":1769504824235,"version":"3.49.0"},"reference-count":46,"publisher":"Bentham Science Publishers Ltd.","issue":"6","funder":[{"DOI":"10.13039\/501100009330","name":"Medical Science and Technology Research Fund of Guangdong Province","doi-asserted-by":"publisher","award":["B2022310"],"award-info":[{"award-number":["B2022310"]}],"id":[{"id":"10.13039\/501100009330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAD"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n<jats:title>Aims:<\/jats:title>\n<jats:p>This study aims to evaluate the efficacy and safety of PARP inhibitor therapy in\nadvanced ovarian cancer and identify the optimal treatment for the survival of patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The diversity of PARP inhibitors makes clinicians confused about the optimal strategy and the most effective BRCAm mutation-based regimen for the survival of patients with advanced ovarian cancer.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>The objective of this study is to compare the effects of various PARP inhibitors alone\nor in combination with other agents in advanced ovarian cancer.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>PubMed, Embase, Cochrane Library, and Web of Science were searched for relevant\nstudies on PARP inhibitors for ovarian cancer. Bayesian network meta-analysis was performed\nusing Stata 15.0 and R 4.0.4. The primary outcome was the overall PFS, and the secondary outcomes included OS, AE3, DISAE, and TFST.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Fifteen studies involving 5,788 participants were included. The Bayesian network metaanalysis results showed that olaparibANDAI was the most beneficial in prolonging overall PFS\nand non-BRCAm PFS, followed by niraparibANDAI. However, for BRCAm patients, olaparibTR\nmight be the most effective, followed by niraparibANDAI. Olaparib was the most effective for\nthe OS of BRCAm patients. AI, olaparibANDAI, and veliparibTR were more likely to induce\ngrade 3 or higher adverse events. AI and olaparibANDAI were more likely to cause DISAE.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>PARP inhibitors are beneficial to the survival of patients with advanced ovarian cancer. The olaparibTR is the most effective for BRCAm patients, whereas olaparibANDAI and niraparibANDAI are preferable for non-BRCAm patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Other:<\/jats:title>\n<jats:p>More high-quality studies are desired to investigate the efficacy and safety of PARP inhibitors in patients with other genetic performances.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573409920666230907093331","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T04:23:21Z","timestamp":1694406201000},"page":"736-751","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of PARP Inhibitor Therapy in Advanced Ovarian\nCancer: A Systematic Review and Network Meta-analysis of Randomized\nControlled Trials"],"prefix":"10.2174","volume":"20","author":[{"given":"Juying","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Guangzhou Concord Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaozhe","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guangzhou Concord Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhe","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Jiahui International Hospital, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoshan","family":"Lian","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shenzhen New Frontier United Family\nHospital, Shenzhen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guangzhou Concord Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangbo","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Guangzhou Concord Cancer Center, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"Sung H.","year":"2021","unstructured":"Sung H.; Ferlay J.; Siegel R.L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F.; Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2021,71(3),209-249","journal-title":"CA Cancer J Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"Torre L.A.","year":"2018","unstructured":"Torre L.A.; Trabert B.; DeSantis C.E.; Miller K.D.; Samimi G.; Runowicz C.D.; Gaudet M.M.; Jemal A.; Siegel R.L.; Ovarian cancer statistics, 2018. CA Cancer J Clin  2018,68(4),284-296","journal-title":"CA Cancer J Clin"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","volume":"24","author":"Ledermann J.A.","year":"2013","unstructured":"Ledermann J.A.; Raja F.A.; Fotopoulou C.; Gonzalez-Martin A.; Colombo N.; Sessa C.; Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol  2013,24(6),vi24-vi32","journal-title":"Ann Oncol"},{"key":"ref=4","first-page":"64","volume":"8","author":"Oncology C.S.G.","year":"2022","unstructured":"Oncology C.S.G.; Clinical guidelines of PARP inhibitors in ovarian cancer. Elect J Integr Can The  2022,8(3),64-77","journal-title":"Elect J Integr Can The"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","volume":"26","author":"Ashworth A.","year":"2008","unstructured":"Ashworth A.; A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol  2008,26(22),3785-3790","journal-title":"J Clin Oncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.2147\/OTT.S139336","volume":"10","author":"Ohmoto A.","year":"2017","unstructured":"Ohmoto A.; Yachida S.; Current status of poly(ADP-ribose) polymerase inhibitors and future directions. OncoTargets Ther  2017,10,5195-5208","journal-title":"OncoTargets Ther"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrm.2017.48","volume":"18","author":"Chang H.H.Y.","year":"2017","unstructured":"Chang H.H.Y.; Pannunzio N.R.; Adachi N.; Lieber M.R.; Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol  2017,18(8),495-506","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"793884","DOI":"10.3389\/fgene.2022.793884","volume":"13","author":"Kieffer S.R.","year":"2022","unstructured":"Kieffer S.R.; Lowndes N.F.; Immediate-early, early, and late responses to dna double stranded breaks. Front Genet  2022,13,793884","journal-title":"Front Genet"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1093\/nar\/gkaa022","volume":"48","author":"Yang G.","year":"2020","unstructured":"Yang G.; Chen Y.; Wu J.; Chen S.H.; Liu X.; Singh A.K.; Yu X.; Poly(ADP-ribosyl)ation mediates early phase histone eviction at DNA lesions. Nucleic Acids Res  2020,48(6),3001-3013","journal-title":"Nucleic Acids Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1093\/nar\/gky088","volume":"46","author":"Yang G.","year":"2018","unstructured":"Yang G.; Liu C.; Chen S.H.; Kassab M.A.; Hoff J.D.; Walter N.G.; Yu X.; Super-resolution imaging identifies PARP1 and the Ku complex acting as DNA double-strand break sensors. Nucleic Acids Res  2018,46(7),3446-3457","journal-title":"Nucleic Acids Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"9605","DOI":"10.1093\/nar\/gkr656","volume":"39","author":"Cheng Q.","year":"2011","unstructured":"Cheng Q.; Barboule N.; Frit P.; Gomez D.; Bombarde O.; Couderc B.; Ren G.S.; Salles B.; Calsou P.; Ku counteracts mobilization of PARP1 and MRN in chromatin damaged with DNA double-strand breaks. Nucleic Acids Res  2011,39(22),9605-9619","journal-title":"Nucleic Acids Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"12154","DOI":"10.1038\/ncomms12154","volume":"7","author":"Mao P.","year":"2016","unstructured":"Mao P.; Liu J.; Zhang Z.; Zhang H.; Liu H.; Gao S.; Rong Y.S.; Zhao Y.; Homologous recombination-dependent repair of telomeric DSBs in proliferating human cells. Nat Commun  2016,7(1),12154","journal-title":"Nat Commun"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-18-1314","volume":"24","author":"Konstantinopoulos P.A.","year":"2018","unstructured":"Konstantinopoulos P.A.; Matulonis U.A.; PARP inhibitors in ovarian cancer: A trailblazing and transformative journey. Clin Cancer Res  2018,24(17),4062-4065","journal-title":"Clin Cancer Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-21-3023","volume":"28","author":"Gao Q.","year":"2022","unstructured":"Gao Q.; Zhu J.; Zhao W.; Huang Y.; An R.; Zheng H.; Qu P.; Wang L.; Zhou Q.; Wang D.; Lou G.; Wang J.; Wang K.; Low J.; Kong B.; Rozita A.M.; Sen L.C.; Yin R.; Xie X.; Liu J.; Sun W.; Su J.; Zhang C.; Zang R.; Ma D.; Olaparib maintenance monotherapy in asian patients with platinum-sensitive relapsed ovarian cancer: Phase III Trial (L-MOCA). Clin Cancer Res  2022,28(11),2278-2285","journal-title":"Clin Cancer Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ygyno.2022.01.034","volume":"165","author":"Vanderstichele A.","year":"2022","unstructured":"Vanderstichele A.; Loverix L.; Busschaert P.; Van Nieuwenhuysen E.; Han S.N.; Concin N.; Callewaert T.; Olbrecht S.; Salihi R.; Berteloot P.; Neven P.; Lambrechts D.; Van Gorp T.; Vergote I.; Randomized CLIO\/BGOG-ov10 trial of olaparib monotherapy versus physician\u2019s choice chemotherapy in relapsed ovarian cancer. Gynecol Oncol  2022,165(1),14-22","journal-title":"Gynecol Oncol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ygyno.2021.12.025","volume":"164","author":"Poveda A.","year":"2022","unstructured":"Poveda A.; Lheureux S.; Colombo N.; Cibula D.; Lindemann K.; Weberpals J.; Bjurberg M.; Oaknin A.; Sikorska M.; Gonz\u00e1lez-Mart\u00edn A.; Madry R.; P\u00e9rez M.J.R.; Ledermann J.; Davidson R.; Blakeley C.; Bennett J.; Barnicle A.; \u0160kof E.; Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1\/BRCA2 mutation: OPINION primary analysis. Gynecol Oncol  2022,164(3),498-504","journal-title":"Gynecol Oncol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"Banerjee S.","year":"2021","unstructured":"Banerjee S.; Moore K.N.; Colombo N.; Scambia G.; Kim B.G.; Oaknin A.; Friedlander M.; Lisyanskaya A.; Floquet A.; Leary A.; Sonke G.S.; Gourley C.; Oza A.; Gonz\u00e1lez-Mart\u00edn A.; Aghajanian C.; Bradley W.H.; Holmes E.; Lowe E.S.; DiSilvestro P.; Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol  2021,22(12),1721-1731","journal-title":"Lancet Oncol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1470-2045(19)30515-7","volume":"20","author":"Mirza M.R.","year":"2019","unstructured":"Mirza M.R.; \u00c5vall Lundqvist E.; Birrer M.J.; dePont Christensen R.; Nyvang G.B.; Malander S.; Anttila M.; Werner T.L.; Lund B.; Lindahl G.; Hietanen S.; Peen U.; Dimoula M.; Roed H.; \u00d8r Knudsen A.; Staff S.; Krog Vistisen A.; Bj\u00f8rge L.; M\u00e4enp\u00e4 J.U.; Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2\/ENGOT-ov24): A randomised, phase 2, superiority trial. Lancet Oncol  2019,20(10),1409-1419","journal-title":"Lancet Oncol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","volume":"381","author":"Coleman R.L.","year":"2019","unstructured":"Coleman R.L.; Fleming G.F.; Brady M.F.; Swisher E.M.; Steffensen K.D.; Friedlander M.; Okamoto A.; Moore K.N.; Efrat Ben-Baruch N.; Werner T.L.; Cloven N.G.; Oaknin A.; DiSilvestro P.A.; Morgan M.A.; Nam J.H.; Leath C.A.; Nicum S.; Hagemann A.R.; Littell R.D.; Cella D.; Baron-Hay S.; Garcia-Donas J.; Mizuno M.; Bell-McGuinn K.; Sullivan D.M.; Bach B.A.; Bhattacharya S.; Ratajczak C.K.; Ansell P.J.; Dinh M.H.; Aghajanian C.; Bookman M.A.; Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med  2019,381(25),2403-2415","journal-title":"N Engl J Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"Ray-Coquard I.","year":"2019","unstructured":"Ray-Coquard I.; Pautier P.; Pignata S.; P\u00e9rol D.; Gonz\u00e1lez-Mart\u00edn A.; Berger R.; Fujiwara K.; Vergote I.; Colombo N.; M\u00e4enp\u00e4 J.; Selle F.; Sehouli J.; Lorusso D.; Guerra Al\u00eda E.M.; Reinthaller A.; Nagao S.; Lefeuvre-Plesse C.; Canzler U.; Scambia G.; Lortholary A.; Marm\u00e9 F.; Combe P.; de Gregorio N.; Rodrigues M.; Buderath P.; Dubot C.; Burges A.; You B.; Pujade-Lauraine E.; Harter P.; Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med  2019,381(25),2416-2428","journal-title":"N Engl J Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"Hutton B.","year":"2015","unstructured":"Hutton B.; Salanti G.; Caldwell D.M.; Chaimani A.; Schmid C.H.; Cameron C.; Ioannidis J.P.A.; Straus S.; Thorlund K.; Jansen J.P.; Mulrow C.; Catal\u00e1-L\u00f3pez F.; G\u00f8tzsche P.C.; Dickersin K.; Boutron I.; Altman D.G.; Moher D.; The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann Intern Med  2015,162(11),777-784","journal-title":"Ann Intern Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/jep.13159","volume":"26","author":"Lin L.","year":"2020","unstructured":"Lin L.; Comparison of four heterogeneity measures for meta\u2010analysis. J Eval Clin Pract  2020,26(1),376-384","journal-title":"J Eval Clin Pract"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"d549","DOI":"10.1136\/bmj.d549","volume":"342","author":"Riley R.D.","year":"2011","unstructured":"Riley R.D.; Higgins J.P.T.; Deeks J.J.; Interpretation of random effects meta-analyses. BMJ  2011,342(feb10 2),d549","journal-title":"BMJ"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","volume":"30","author":"Kaye S.B.","year":"2012","unstructured":"Kaye S.B.; Lubinski J.; Matulonis U.; Ang J.E.; Gourley C.; Karlan B.Y.; Amnon A.; Bell-McGuinn K.M.; Chen L.M.; Friedlander M.; Safra T.; Vergote I.; Wickens M.; Lowe E.S.; Carmichael J.; Kaufman B.; Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol  2012,30(4),372-379","journal-title":"J Clin Oncol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"Ledermann J.","year":"2012","unstructured":"Ledermann J.; Harter P.; Gourley C.; Friedlander M.; Vergote I.; Rustin G.; Scott C.; Meier W.; Shapira-Frommer R.; Safra T.; Matei D.; Macpherson E.; Watkins C.; Carmichael J.; Matulonis U.; Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med  2012,366(15),1382-1392","journal-title":"N Engl J Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"Ledermann J.","year":"2014","unstructured":"Ledermann J.; Harter P.; Gourley C.; Friedlander M.; Vergote I.; Rustin G.; Scott C.L.; Meier W.; Shapira-Frommer R.; Safra T.; Matei D.; Fielding A.; Spencer S.; Dougherty B.; Orr M.; Hodgson D.; Barrett J.C.; Matulonis U.; Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol  2014,15(8),852-861","journal-title":"Lancet Oncol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","volume":"15","author":"Liu J.F.","year":"2014","unstructured":"Liu J.F.; Barry W.T.; Birrer M.; Lee J.M.; Buckanovich R.J.; Fleming G.F.; Rimel B.J.; Buss M.K.; Nattam S.; Hurteau J.; Luo W.; Quy P.; Whalen C.; Obermayer L.; Lee H.; Winer E.P.; Kohn E.C.; Ivy S.P.; Matulonis U.A.; Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 study. Lancet Oncol  2014,15(11),1207-1214","journal-title":"Lancet Oncol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","volume":"16","author":"Oza A.M.","year":"2015","unstructured":"Oza A.M.; Cibula D.; Benzaquen A.O.; Poole C.; Mathijssen R.H.J.; Sonke G.S.; Colombo N.; \u0160pa\u010dek J.; Vuylsteke P.; Hirte H.; Mahner S.; Plante M.; Schmalfeldt B.; Mackay H.; Rowbottom J.; Lowe E.S.; Dougherty B.; Barrett J.C.; Friedlander M.; Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncol  2015,16(1),87-97","journal-title":"Lancet Oncol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","volume":"17","author":"Ledermann J.A.","year":"2016","unstructured":"Ledermann J.A.; Harter P.; Gourley C.; Friedlander M.; Vergote I.; Rustin G.; Scott C.; Meier W.; Shapira-Frommer R.; Safra T.; Matei D.; Fielding A.; Spencer S.; Rowe P.; Lowe E.; Hodgson D.; Sovak M.A.; Matulonis U.; Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: An updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol  2016,17(11),1579-1589","journal-title":"Lancet Oncol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"Mirza M.R.","year":"2016","unstructured":"Mirza M.R.; Monk B.J.; Herrstedt J.; Oza A.M.; Mahner S.; Redondo A.; Fabbro M.; Ledermann J.A.; Lorusso D.; Vergote I.; Ben-Baruch N.E.; Marth C.; M\u0105dry R.; Christensen R.D.; Berek J.S.; D\u00f8rum A.; Tinker A.V.; du Bois A.; Gonz\u00e1lez-Mart\u00edn A.; Follana P.; Benigno B.; Rosenberg P.; Gilbert L.; Rimel B.J.; Buscema J.; Balser J.P.; Agarwal S.; Matulonis U.A.; Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med  2016,375(22),2154-2164","journal-title":"N Engl J Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"Coleman R.L.","year":"2017","unstructured":"Coleman R.L.; Oza A.M.; Lorusso D.; Aghajanian C.; Oaknin A.; Dean A.; Colombo N.; Weberpals J.I.; Clamp A.; Scambia G.; Leary A.; Holloway R.W.; Gancedo M.A.; Fong P.C.; Goh J.C.; O\u2019Malley D.M.; Armstrong D.K.; Garcia-Donas J.; Swisher E.M.; Floquet A.; Konecny G.E.; McNeish I.A.; Scott C.L.; Cameron T.; Maloney L.; Isaacson J.; Goble S.; Grace C.; Harding T.C.; Raponi M.; Sun J.; Lin K.K.; Giordano H.; Ledermann J.A.; Buck M.; Dean A.; Friedlander M.L.; Goh J.C.; Harnett P.; Kichenadasse G.; Scott C.L.; Denys H.; Dirix L.; Vergote I.; Elit L.; Ghatage P.; Oza A.M.; Plante M.; Provencher D.; Weberpals J.I.; Welch S.; Floquet A.; Gladieff L.; Joly F.; Leary A.; Lortholary A.; Lotz J.; Medioni J.; Tredan O.; You B.; El-Balat A.; H\u00e4nle C.; Krabisch P.; Neunh\u00f6ffer T.; P\u00f6lcher M.; Wimberger P.; Amit A.; Kovel S.; Leviov M.; Safra T.; Shapira-Frommer R.; Stemmer S.; Bologna A.; Colombo N.; Lorusso D.; Pignata S.; Sabbatini R.F.; Scambia G.; Tamberi S.; Zamagni C.; Fong P.C.; O\u2019Donnell A.; Gancedo M.A.; Herraez A.C.; Garcia-Donas J.; Guerra E.M.; Oaknin A.; Palacio I.; Romero I.; Sanchez A.; Banerjee S.N.; Clamp A.; Drew Y.; Gabra H.G.; Jackson D.; Ledermann J.A.; McNeish I.A.; Parkinson C.; Powell M.; Aghajanian C.; Armstrong D.K.; Birrer M.J.; Buss M.K.; Chambers S.K.; Chen L.; Coleman R.L.; Holloway R.W.; Konecny G.E.; Ma L.; Morgan M.A.; Morris R.T.; Mutch D.G.; O\u2019Malley D.M.; Slomovitz B.M.; Swisher E.M.; Vanderkwaak T.; Vulfovich M.; Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet  2017,390(10106),1949-1961","journal-title":"Lancet"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"Pujade-Lauraine E.","year":"2017","unstructured":"Pujade-Lauraine E.; Ledermann J.A.; Selle F.; Gebski V.; Penson R.T.; Oza A.M.; Korach J.; Huzarski T.; Poveda A.; Pignata S.; Friedlander M.; Colombo N.; Harter P.; Fujiwara K.; Ray-Coquard I.; Banerjee S.; Liu J.; Lowe E.S.; Bloomfield R.; Pautier P.; Korach J.; Huzarski T.; Byrski T.; Pautier P.; Friedlander M.; Harter P.; Colombo N.; Pignata S.; Scambia G.; Nicoletto M.; Nussey F.; Clamp A.; Penson R.; Oza A.; Poveda Velasco A.; Rodrigues M.; Lotz J-P.; Selle F.; Ray-Coquard I.; Provencher D.; Prat Aparicio A.; Vidal Boixader L.; Scott C.; Tamura K.; Yunokawa M.; Lisyanskaya A.; Medioni J.; P\u00e9cuchet N.; Dubot C.; de la Motte Rouge T.; Kaminsky M-C.; Weber B.; Lortholary A.; Parkinson C.; Ledermann J.; Williams S.; Banerjee S.; Cosin J.; Hoffman J.; Penson R.; Plante M.; Covens A.; Sonke G.; Joly F.; Floquet A.; Banerjee S.; Hirte H.; Amit A.; Park-Simon T-W.; Matsumoto K.; Tjulandin S.; Kim J.H.; Gladieff L.; Sabbatini R.; O\u2019Malley D.; Timmins P.; Kredentser D.; La\u00ednez Milagro N.; Barretina Ginesta M.P.; Tibau Martorell A.; G\u00f3mez de Lia\u00f1o Lista A.; Ojeda Gonz\u00e1lez B.; Mileshkin L.; Mandai M.; Boere I.; Ottevanger P.; Nam J-H.; Filho E.; Hamizi S.; Cognetti F.; Warshal D.; Dickson-Michelson E.; Kamelle S.; McKenzie N.; Rodriguez G.; Armstrong D.; Chalas E.; Celano P.; Behbakht K.; Davidson S.; Welch S.; Helpman L.; Fishman A.; Bruchim I.; Sikorska M.; S\u0142owi\u0144ska A.; Rogowski W.; Bidzi\u0144ski M.; \u015apiewankiewicz B.; Casado Herraez A.; Mendiola Fern\u00e1ndez C.; Gropp-Meier M.; Saito T.; Takehara K.; Enomoto T.; Watari H.; Choi C.H.; Kim B-G.; Kim J.W.; Hegg R.; Vergote I.; Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol  2017,18(9),1274-1284","journal-title":"Lancet Oncol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"Moore K.","year":"2018","unstructured":"Moore K.; Colombo N.; Scambia G.; Kim B.G.; Oaknin A.; Friedlander M.; Lisyanskaya A.; Floquet A.; Leary A.; Sonke G.S.; Gourley C.; Banerjee S.; Oza A.; Gonz\u00e1lez-Mart\u00edn A.; Aghajanian C.; Bradley W.; Mathews C.; Liu J.; Lowe E.S.; Bloomfield R.; DiSilvestro P.; Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med  2018,379(26),2495-2505","journal-title":"N Engl J Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn A.","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A.; Pothuri B.; Vergote I.; DePont Christensen R.; Graybill W.; Mirza M.R.; McCormick C.; Lorusso D.; Hoskins P.; Freyer G.; Baumann K.; Jardon K.; Redondo A.; Moore R.G.; Vulsteke C.; O\u2019Cearbhaill R.E.; Lund B.; Backes F.; Barretina-Ginesta P.; Haggerty A.F.; Rubio-P\u00e9rez M.J.; Shahin M.S.; Mangili G.; Bradley W.H.; Bruchim I.; Sun K.; Malinowska I.A.; Li Y.; Gupta D.; Monk B.J.; Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med  2019,381(25),2391-2402","journal-title":"N Engl J Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/annonc\/mdz018","volume":"30","author":"Liu J.F.","year":"2019","unstructured":"Liu J.F.; Barry W.T.; Birrer M.; Lee J.M.; Buckanovich R.J.; Fleming G.F.; Rimel B.J.; Buss M.K.; Nattam S.R.; Hurteau J.; Luo W.; Curtis J.; Whalen C.; Kohn E.C.; Ivy S.P.; Matulonis U.A.; Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol  2019,30(4),551-557","journal-title":"Ann Oncol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S1470-2045(20)30061-9","volume":"21","author":"Ledermann J.A.","year":"2020","unstructured":"Ledermann J.A.; Oza A.M.; Lorusso D.; Aghajanian C.; Oaknin A.; Dean A.; Colombo N.; Weberpals J.I.; Clamp A.R.; Scambia G.; Leary A.; Holloway R.W.; Gancedo M.A.; Fong P.C.; Goh J.C.; O\u2019Malley D.M.; Armstrong D.K.; Banerjee S.; Garc\u00eda-Donas J.; Swisher E.M.; Cameron T.; Maloney L.; Goble S.; Coleman R.L.; Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): Post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol  2020,21(5),710-722","journal-title":"Lancet Oncol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1200\/JCO.19.02745","volume":"38","author":"Penson R.T.","year":"2020","unstructured":"Penson R.T.; Valencia R.V.; Cibula D.; Colombo N.; Leath C.A.; Bidzi\u0144ski M.; Kim J.W.; Nam J.H.; Madry R.; Hern\u00e1ndez C.; Mora P.A.R.; Ryu S.Y.; Milenkova T.; Lowe E.S.; Barker L.; Scambia G.; Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline brca1\/2 mutation (SOLO3): A randomized phase iii trial. J Clin Oncol  2020,38(11),1164-1174","journal-title":"J Clin Oncol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ygyno.2021.12.003","volume":"164","author":"Swisher E.M.","year":"2022","unstructured":"Swisher E.M.; Aghajanian C.; O\u2019Malley D.M.; Fleming G.F.; Kaufmann S.H.; Levine D.A.; Birrer M.J.; Moore K.N.; Spirtos N.M.; Shahin M.S.; Reid T.J.; Friedlander M.; Steffensen K.D.; Okamoto A.; Sehgal V.; Ansell P.J.; Dinh M.H.; Bookman M.A.; Coleman R.L.; Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA\/GOG-3005 study. Gynecol Oncol  2022,164(2),245-253","journal-title":"Gynecol Oncol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ygyno.2020.10.005","volume":"160","author":"Wu L.","year":"2021","unstructured":"Wu L.; Zhu J.; Yin R.; Wu X.; Lou G.; Wang J.; Gao Y.; Kong B.; Lu X.; Zhou Q.; Wang Y.; Chen Y.; Lu W.; Li W.; Cheng Y.; Liu J.; Ma X.; Zhang J.; Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and\/or BRCA2 mutation: SOLO1 China cohort. Gynecol Oncol  2021,160(1),175-181","journal-title":"Gynecol Oncol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"Poveda A.","year":"2021","unstructured":"Poveda A.; Floquet A.; Ledermann J.A.; Asher R.; Penson R.T.; Oza A.M.; Korach J.; Huzarski T.; Pignata S.; Friedlander M.; Baldoni A.; Park-Simon T.W.; Tamura K.; Sonke G.S.; Lisyanskaya A.; Kim J.H.; Filho E.A.; Milenkova T.; Lowe E.S.; Rowe P.; Vergote I.; Pujade-Lauraine E.; Korach J.; Huzarski T.; Byrski T.; Pautier P.; Friedlander M.; Harter P.; Colombo N.; Pignata S.; Scambia G.; Nicoletto M.; Nussey F.; Clamp A.; Penson R.; Oza A.; Poveda Velasco A.; Rodrigues M.; Lotz J-P.; Selle F.; Ray-Coquard I.; Provencher D.; Prat Aparicio A.; Vidal Boixader L.; Scott C.; Tamura K.; Yunokawa M.; Lisyanskaya A.; Medioni J.; P\u00e9cuchet N.; Dubot C.; De La Motte Rouge T.; Kaminsky M-C.; Weber B.; Lortholary A.; Parkinson C.; Ledermann J.; Williams S.; Banerjee S.; Cosin J.; Hoffman J.; Penson R.; Plante M.; Covens A.; Sonke G.; Joly F.; Floquet A.; Banerjee S.; Hirte H.; Amit A.; Park-Simon T-W.; Matsumoto K.; Tjulandin S.; Hoon Kim J.; Gladieff L.; Sabbatini R.; O\u2019Malley D.; Timmins P.; Kredentser D.; La\u00ednez Milagro N.; Barretina Ginesta M.P.; Tibau Martorell A.; G\u00f3mez De Lia\u00f1o Lista A.; Ojeda Gonz\u00e1lez B.; Mileshkin L.; Mandai M.; Boere I.; Ottevanger P.; Nam J-H.; Filho E.; Hamizi S.; Cognetti F.; Warshal D.; Dickson-Michelson E.; Kamelle S.; McKenzie N.; Rodriguez G.; Armstrong D.; Chalas E.; Celano P.; Behbakht K.; Davidson S.; Welch S.; Helpman L.; Fishman A.; Bruchim I.; Sikorska M.; S\u0142owi\u0144ska A.; Rogowski W.; Bidzi\u0144ski M.; \u015apiewankiewicz B.; Casado Herraez A.; Mendiola Fern\u00e1ndez C.; Gropp-Meier M.; Saito T.; Takehara K.; Enomoto T.; Watari H.; Choi C.H.; Kim B-G.; Weon Kim J.; Hegg R.; Vergote I.; Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol  2021,22(5),620-631","journal-title":"Lancet Oncol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","volume":"32","author":"Wu X.H.","year":"2021","unstructured":"Wu X.H.; Zhu J.Q.; Yin R.T.; Yang J.X.; Liu J.H.; Wang J.; Wu L.Y.; Liu Z.L.; Gao Y.N.; Wang D.B.; Lou G.; Yang H.Y.; Zhou Q.; Kong B.H.; Huang Y.; Chen L.P.; Li G.L.; An R.F.; Wang K.; Zhang Y.; Yan X.J.; Lu X.; Lu W.G.; Hao M.; Wang L.; Cui H.; Chen Q.H.; Abulizi G.; Huang X.H.; Tian X.F.; Wen H.; Zhang C.; Hou J.M.; Mirza M.R.; Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): A randomized, double-blind, placebo-controlled phase III trial\u2606. Ann Oncol  2021,32(4),512-521","journal-title":"Ann Oncol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.1158\/1078-0432.CCR-10-0527","volume":"16","author":"Chan N.","year":"2010","unstructured":"Chan N.; Bristow R.G.; \u201cContextual\u201d synthetic lethality and\/or loss of heterozygosity: Tumor hypoxia and modification of DNA repair. Clin Cancer Res  2010,16(18),4553-4560","journal-title":"Clin Cancer Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1073\/pnas.0904783107","volume":"107","author":"Hegan D.C.","year":"2010","unstructured":"Hegan D.C.; Lu Y.; Stachelek G.C.; Crosby M.E.; Bindra R.S.; Glazer P.M.; Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci  2010,107(5),2201-2206","journal-title":"Proc Natl Acad Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"Perren T.J.","year":"2011","unstructured":"Perren T.J.; Swart A.M.; Pfisterer J.; Ledermann J.A.; Pujade-Lauraine E.; Kristensen G.; Carey M.S.; Beale P.; Cervantes A.; Kurzeder C.; Bois A.; Sehouli J.; Kimmig R.; St\u00e4hle A.; Collinson F.; Essapen S.; Gourley C.; Lortholary A.; Selle F.; Mirza M.R.; Leminen A.; Plante M.; Stark D.; Qian W.; Parmar M.K.B.; Oza A.M.; A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med  2011,365(26),2484-2496","journal-title":"N Engl J Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"Burger R.A.","year":"2011","unstructured":"Burger R.A.; Brady M.F.; Bookman M.A.; Fleming G.F.; Monk B.J.; Huang H.; Mannel R.S.; Homesley H.D.; Fowler J.; Greer B.E.; Boente M.; Birrer M.J.; Liang S.X.; Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med  2011,365(26),2473-2483","journal-title":"N Engl J Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","volume":"24","author":"Norquist B.M.","year":"2018","unstructured":"Norquist B.M.; Brady M.F.; Harrell M.I.; Walsh T.; Lee M.K.; Gulsuner S.; Bernards S.S.; Casadei S.; Burger R.A.; Tewari K.S.; Backes F.; Mannel R.S.; Glaser G.; Bailey C.; Rubin S.; Soper J.; Lankes H.A.; Ramirez N.C.; King M.C.; Birrer M.J.; Swisher E.M.; Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: An NRG oncology\/gynecologic oncology group study. Clin Cancer Res  2018,24(4),777-783","journal-title":"Clin Cancer Res"}],"container-title":["Current Computer-Aided Drug Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573409920666230907093331","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/220774\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573409920666230907093331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T13:16:56Z","timestamp":1722345416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/220774\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573409920666230907093331","relation":{},"ISSN":["1573-4099"],"issn-type":[{"value":"1573-4099","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}